About DualityBio

DualityBio is a clinical-stage innovative biopharmaceutical company dedicated to developing next-generation antibody-drug conjugates (ADCs) for patients with cancer and autoimmune diseases. The company has successfully established multiple next-generation ADC technology platforms with global intellectual property rights.

Based on in-depth research and exploration of the biological mechanisms of diseases, DualityBio boasts a robust clinical ADC pipeline. It has initiated a number of global multicenter clinical trials across more than 20 countries, with over 2,600 patients enrolled. Meanwhile, DualityBio has entered into multiple overseas licensing collaborations with global pharmaceutical companies and leading innovative biopharmas.

As a global ADC innovation engine, DualityBio continues to develop the next generation of novel ADCs, including bispecific antibody-drug conjugates (bispecific ADCs), ADCs with payloads of new mechanisms, and autoimmune ADCs.

For more information, please visit www.dualitybiologics.com.

Media Contact: PR@dualitybiologics.com

Investor Contact: IR@dualitybiologics.com

Drug supply project

For more information, please

follow the official WeChat public

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai